DrugS

The American Society of Clinical Oncology and the Association for Clinical Oncology (collectively ASCO) are closely monitoring the current, acute shortages of cisplatin and carboplatin in the United States. ASCO has developed guidance for clinicians who are navigating the situation and offered recommendations to policymakers to help mitigate the current shortages and prevent similar situations in the future. 

ASCO has a dedicated drug shortages website that will be kept up to date as information on the availability of drugs in shortage is released from the Food and Drug Administration (FDA). The site also offers clinician resources and links to more information.

We strongly encourages our members to report drug shortages directly to FDA. While the agency is aware of critical shortages, it is important that it receives these reports to better assess the scope of shortages and use in mitigation activities.

ASCO will remain in close contact with FDA and will also continue to share its concerns and recommendations with Congress. Use the ACT Network to urge lawmakers to take the organization’s recommended steps to mitigate drug shortages.

Bookmark asco.org/drugshortages to stay up to date on the current shortage of cancer drug treatments, as well as breaking news, advocacy, and analysis on cancer policy. 

In follow up to the discussions held at the spring State Affiliate Council meeting, the Food and Drug Administration (FDA) expects additional releases of cisplatin from Accord Table of Contents Encourage your members to join the State Society Network Healthcare in the upcoming days. Providers and others can check on Accord supplies through their usual channels and can also contact the company directly at 866-941-7875, Option 2.

The FDA has additional information on the cisplatin shortage, including expected recovery dates from other manufacturers.

The FDA is exploring all avenues for additional supplies to ensure patient need will be met, including temporary importation. The American Society of Clinical Oncology will keep its members informed as supply becomes available.

Information from Merck announcing a new indication linked below.

Click to Download.

For prescribers: please click here for state-required price disclosures.

On January 27, 2023, the National Comprehensive Cancer Network® (NCCN®) revised its guidelines—now ribociclib (KISQALI®) is the only CDK4/6 inhibitor in combination with an AI designated as a Category 1 Preferred regimen in first-line HR+/HER2- mBC.1,2

Can we set up some time to further explore this major update and review the data that made the NCCN differentiate ribociclib (KISQALI) for first-line use in combination with an AI? Please feel free to contact me at (802) 735-7859 or via email. 

See the evidence that drove the update

Click here to read the NCCN Guidelines®.

Click here for full Prescribing Information for KISQALI.

Lilly USA, LLC is pleased to announce recent major label changes for Retevmo^® (selpercatinib, 80 mg and 40 mg capsules). Read press release here. 

NCCN GUIDELINES^®: Sacituzumab govitecan-hziy (TRODELVY) is recommended as a Category 1 preferred treatment option for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. Read More. 

Learn more about TRODELVY.  Please click to see full Prescribing Information. 

The National Comprehensive Cancer Network® (NCCN®) has published new NCCN Guidelines for Patients®: Breast Cancer Screening and Diagnosis to help people understand their personal risk for breast cancer, when they should begin screening, and how often to screen—in order to detect cancer earlier, for more treatment options and better outcomes. With this information, they are equipped to have more informed conversations with their health care providers and be active decision-makers in their long-term health. Read More. 

The NCCN released new Kidney Cancer guidelines (v1.2023) on June 17th and has elevated Fotivda (tivozanib) to be the only Category 1 recommended regimen, for patients that have failed 2 or more systemic treatments.  More Information.  Full Prescribing Information. 

Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, today reported new data further underscoring the significant burden of disease in adults with pyruvate kinase (PK) deficiency regardless of genotype and supporting the potential benefits of treatment with PYRUKYND® for these patients.  Read More.

Randomized Phase 3 Clinical Trial of ADCETRIS Combination Met Key Secondary OS Endpoint, Demonstrating a 41% Reduction in Risk of Death vs. Standard of Care in Patients With Advanced Hodgkin Lymphoma.  Read More.